Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Syros Pharmaceuticals has raised $45.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2023.
Syros Pharmaceuticals's investors include ARCH Venture Partners, Bain Capital, Samsara BioCapital, Redmile Group, Blue Owl.
Syros Pharmaceuticals is headquartered in Watertown, United States.
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Syros Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Syros Pharmaceuticals — Funding & Investors." VCBacked, December 19, 2023, https://www.vcbacked.co/company/syros-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2023). Syros Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/syros-pharmaceuticals
{{cite web |title=Syros Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/syros-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated